


Claims for Examination

1. A compound having the structure:




,





or , or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

3. The compound of claim 1, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.

4. The compound of claim 1, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

5. A composition comprising:

(i) an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof; and


(ii) a pharmaceutically acceptable carrier or vehicle.

6. The composition of claim 5, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

7. The composition of claim 5, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.

8. The composition of claim 5, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.


9. The composition of any one of claims 5-8, further comprising sorafenib or lenvatinib.

10. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof for use in therapy.

11. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prevention of hepatocellular carcinoma in a subject, wherein the compound or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.


12. Use of the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prevention of hepatocellular carcinoma in a subject, wherein the compound, or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.

13. The compound for use of claim 11 or the use of claim 12, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

14. The compound for use of claim 11 or the use of claim 12, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.

15. The compound for use of claim 11 or the use of claim 12, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

16. The compound for use of any one of claims 11-15 or the use of any one of claims 12-15, wherein sorafenib or lenvatinib is to be further administered to the subject.

17. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof for use in the inhibition, reduction or delay of advancement of a subject's liver fibrosis, wherein the compound or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.


18. Use of the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the inhibition, reduction or delay of advancement of a subject's liver fibrosis, wherein the compound or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.

19. The compound for use of claim 17 or the use of claim 18, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

20. The compound for use of claim 17 or the use of claim 18, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.

21. The compound for use of claim 17 or the use of claim 18, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

22. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prevention of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject, wherein the compound or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.


23. Use of the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject, wherein the compound or the pharmaceutically acceptable salt or solvate thereof is to be administered to the subject.

24. The compound for use of claim 22 or the use of claim 23, wherein the compound has the structure




or a pharmaceutically acceptable salt or solvate thereof.

25. The compound for use of claim 22 or the use of claim 23, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.

26. The compound for use of claim 22 or the use of claim 23, wherein the compound has the structure



or a pharmaceutically acceptable salt or solvate thereof.